The efficacy of rosuvastatin calcium tablets combined with calcitriol in the treatment of early diabetic nephropathy and its effects on renal function and inflammatory status
Objective To investigate the effects of combined treatment with rosuvastatin calcium and calcitriol on renal function and inflammatory responses in patients with early-stage diabetic nephropathy.Methods Eighty patients with early diabetic nephropathy who were treated in Shenzhen HengSheng Hospital from October 2022 to January 2024 were selected and randomly divided into the control group and the experimental group,each group of 40 people.The control group received treatment with rosuvastatin calcium alone,while the experimental group received a combination of rosuvastatin calcium and calcitriol.The groups were compared in terms of therapeutic efficacy,renal function indicators(BUN,β2-MG,Cr,Cys-C and urinary albumin excretion rate),inflammatory markers(TNF-α,hs-CRP,IL-6),and renal fibrosis indicators(TGF-β1,Hcy],VEGF).Results Before treatment,there were no significant differences between the two groups in levels of BUN,Cr,β2-MG,Cys-C,urinary albumin excretion rate,TNF-α,hs-CRP,IL-6,TGF-β1,Hcy or VEGF(P＞0.05).After treatment,the trial group showed a higher overall effective rate than the control group(95.00%vs.80.00%)(P＜0.05).The trial group also had lower levels of BUN,β2-MG,Cr,Cys-C and urinary albumin excretion rate than the control group(P＜0.05).Furthermore,the trial group exhibited lower levels of TNF-α,hs-CRP,and IL-6(P＜0.05),and lower levels of TGF-β1,VEGF,and Hcy(P＜0.05).Conclusion Treatment with rosuvastatin calcium combined with calcitriol significantly improves renal function,reduces inflammatory status,and optimizes renal fibrosis indicators in patients with early diabetic nephropathy,offering a new treatment approach for this condition.
Early diabetic nephropathyRosuvastatin calciumCalcitriolRenal functionInflammatory statusRenal fibrosis
万方数据
维普
